332 476
References
[1]
Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol 2015;67:233–8.[2]
Welty CJ, Cowan JE, Nguyen H, et al. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 2015;193:807–11.[3]
Cooperberg MR, Broering JM, Carroll PR. Risk assessment for pros- tate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;101:878–87.[4]
Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173:1938–42.[5]
Eggener SE, Scardino PT, Walsh PC, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185:869–75.[6]
Alam R, Carter HB, Landis P, Epstein JI, Mamawala M. Conditional probability of reclassification in an active surveillance program for prostate cancer. J Urol 2015;193:1950–5.[7]
Cary KC, Cowan JE, Sanford M, et al. Predictors of pathologic progression on biopsy among men on active surveillance for local- ized prostate cancer: the value of the pattern of surveillance biop- sies. Eur Urol 2014;66:337–42.[8]
Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and down- grading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grad- ing system and factoring in tertiary grades. Eur Urol 2012;61: 1019–24.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 2 9 – 3 3 2
332